Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GREAT COMPANY BRZM
#1 Qasp, Bottom is in ready for reversal and NEWS SOON- by next week
pay attention to QASP at these levels
QASP got some cheapies today I feel it will run to .015 soon
Agreed. If we can break the resistances, then it should be a solid week for IVIT.
strong pick this week will also be IVIT
great pick
ACDU, DLAD (Lotto), PDPR, CAMH
TGGI will take a nice bounce here
Anyone here looking for the next DNDN?
AEZS = THE NEW DNDN...CHECK OUT ITS HUGE ONCOLOGICAL PIPELINE!!!
AEterna Zentaris Inc.
(NASDAQ:AEZS)
The company is pending a large inflow of news items for its extensive clinical pipeline, and sources tell us the news is edging towards the positive end. Here is an updated timeline of what to expect:
This may near $3 soon and reach as high as $20-$50 by next year or two. A current market cap of only $80M leaves the door open for plenty of shareholder value opportunities. They will also be attending the ASCO conference in June, increasing transparency and most likely the buying pressure as high profile sources and Wall Street continue to discover this undervalued company.
1) Bone Marrow Cancer: Developing perifosine, the first-in-class oral AKT inhibitor. A Phase III study, the last stage before commercialization, is currently being conducted in the United States for myeloma, a form of bone marrow cancer. Perifosine has been granted a fast-track designation and orphan-drug designation by the FDA.
2) Colon cancer: Keryx is about to start a Phase III study with this same compound in metastatic colon cancer
3) Endometrial cancer and Ovarian cancer: AEZS-108. Conducting a Phase II study in Europe for endometrial cancer and ovarian cancer. We expect to disclose the final results later this year.
4) Bladder cancer, pancreatic cancer and prostate cancer: We also look to possibly conduct other clinical studies in bladder cancer, and pancreatic cancer and refractory prostate cancer
5) In vitro fertilization: In endocrinology we already have a marketed product for in vitro fertilization under the brand name Cetrotide(c). It is being marketed worldwide by Merck Serono, except in Japan, where it's marketed by Nippon Kayaku and Shionogi.
6) Growth hormone deficiency: Our lead endocrinology compound in late-stage development is AEZS-130, which is in Phase III as a diagnostic test for growth hormone deficiency . We also have an orphan-drug designation for this drug in the United States.
7) Currently in discussions with the FDA in order to find the best way to finalize this study for AEZS-130 and file for an approval at the end of this year
8) Children diagnostic test: We are also aiming for diagnostic use of AEZS-130 in children. And the unique selling point of this project is that this will be the first oral diagnostic test.
9) Treat cachexia: AEZS-130 has shown to stimulate appetite and therefore could be used to treat cachexia, a condition which results in a severe reduction of muscle mass and weight loss in patients suffering from conditions such as chronic obstructive pulmonary disease, AIDS and certain cancers.
10) At the pre-clinical development stage, we have some very unique molecules which are dual inhibitors of PI3K and Erk, two hot targets in oncology at present, and also a selective Erk inhibitor.
11) Some of these early-stage projects as well as our more advanced ones will be the object of presentations at major conferences throughout 2010, such as the American Society of Clinical Oncology, ASCO, and American Association of Cancer Research meetings.
Everytime I see that picture.... its just love.
GOOD TO SEE!
NO doubt ACDU is going to get going very soon.
ACDU is going to be a legend!!!!!!!!
it does have great potential
I'm adding ACDU everyday. Monster in the make!!!
ACDU always has alot of buzz. Ready for it to break out huge also don't forget to check out bEDA today
BEDA IS READY TO PAY OFF BIG TIME
BEDA FILINGS FOR THE SHARE REDUCTION POSTED ON THE BEDA BOARD GOING HUGE TOMORROW
ENTI 0018 Ask Breakout Potential
will check AVOE out
thx watching IVOI POSC and BEDA
ENTI 0017 Huge News look for a late run to 004
no I was agreeing with you
Thanks for the heads up on POSC..LOL have a good one and GLTY
DMPD and POSC will fly soon
POCS- News Out- CEO confirms rumor- GREEN Days ahead
http://biomedreports.com/articles/most-popular/36931-positron-chariman-confirms-talks-partnership-or-buy-out-news-may-follow.html
ACDU 0065 Alot of accumulation going on. Looks like the next CDIV as many are buying and holding and locking up the float. Today it is up about 30% much much more to come. Buy and hold. This will go up from here tomorrow and going forward. Go to ACDU board and read the Highlighted stickies very solid company a Diamond in the rough.
AspenBio Pharma Days Away From Announcing Pivotal Study Results For First Ever Appendicitis Blood Diagnostics Test
Investors are banking that results are positive, phase II showcased a 98% sensitivity, much higher than required for 510(k) medical device approvals
Dear Traders,
We are currently working on a report which should be out by tonight on a company which truly could become the next game changer within the biotech stratosphere.We've all been waiting for the next HGSI / DNDN, and it seems that AspenBio Pharma (APPY) has quietly tiptoed into the FDA scene.
Barely getting noticed on its impending phase III results for what could be one of the biggest medical breakthroughs of 2010, a medical blood diagnostics test for appendicitis, a condition that affects nearly 10% of North Americans and has a potential $1B market, whereby (APPY) would have no competition in, thus creating a monopoly similar to say Microsoft with Windows.
FDA News
On 2/9/10, APPY reported conclusions from tis pre-planned independent, interim analysis of an ongoing supplemental trial of AppyScore, the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis, and outline the next steps for its AppyScore 510(k) ifling with the FDA. Based on this, approximately 800 patients were enrolled on 3/23/10. APPY estimates that May 4th to 18th the data analysis will be available to include in its pending 510(k) submission to the FDA which will also come in 2Q10.
Highly Positive Results in Phase II
In September 2007, we announced the results of a 471 patient study conducted at multiple hospital sites under appropriate Institutional Review Board Approvals and patient consent. Out of 471 patients, 100 were normal presumably healthy control donors. The 100 normal AppyScore control individuals were used to characterize and confirm the blood level of the proprietary biomarker used in AppyScore in normal healthy individuals. The remaining 371 were patients who entered to the emergency rooms with abdominal pain, with appendicitis as a possible diagnosis. A total of 97 of 311 or 31% of patients had pathology-confirmed appendicitis in the study. AppyScore was able to correctly identify 95 of 97 patients with pathology-confirmed appendicitis. This exceptionally high sensitivity level of 98% for detecting the actual disease condition is considered statistically significant (95% CI = 93% to 99.9%). In addition, the combination of using the data from AppyScore in conjunction with a CT scan resulted in a specificity of 99% (95% CI = 97% to 99.9%).
nice call newguy417...
from realestate to stocks...location location location...wtg!!
more coming on this play...loong ffrom done.
Who has the #1 Pick
WHERE PEOPLE CAN COME TOGETHER TO DISCUSS THE BEST PENNY STOCK 5,10, AND 20 BAGGERS!!!!!!.
Any investment pick here is based on our opinion only please do your own DD before investing.
SIGN UP FOR OUR EMAIL LIST TO GET THE LASTEST PICKS FOR THE WEEK!!
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |